Jamie Kang

[International Immunopharmacology] Researchers focused on the outer membrane proteins Omp25 and BP26 of Brucella as targets, employing a multidimensional strategy to develop novel mRNA vaccines and systematically evaluate their immunoprotective efficacy.

[Vaccine] Scientists reported that multi-subtype neuraminidase and M2 ectodomain repeatvirus-like particle vaccine conferred higher efficacy of broad cross-protection after two doses of intranasal delivery than intramuscular injection.

[Medical Microbiology and Immunology] Investigators studied the impact of Staphylococcus aureus colonization and abscess events on plasma anti-αGal antibody levels.

[Trends In Microbiology] Scientists explore key host-directed therapys, including cytokine therapy, CAR-T cell therapy and immune checkpoint inhibitors, which target Mycobacterium tuberculosis-infected cells, enhance immune responses, and mitigate inflammation.

[Experimental Hematology & Oncology] The authors delve into the contributions of various known viruses—specifically Epstein-Barr virus, HIV, human T cell leukemia virus type 1, Kaposi’s sarcoma-associated herpesvirus, human cytomegalovirus, hepatitis B virus, hepatitis C virus, and human papillomavirus—in the development of haematological malignancies.

[Invivyyd, Inc.] Invivyd, Inc. announced it has initiated a discovery program for a measles monoclonal antibody.